UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
| x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2015
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
| Commission File Number |
Exact name of registrant as specified in its charter, principal office and address and telephone number |
State of incorporation or organization |
I.R.S. Employer Identification No. | |||
| 001-36867 | Allergan plc Clonshaugh Business and Technology Park Coolock, Dublin, D17 E400, Ireland (862) 261-7000 |
Ireland | 98-1114402 | |||
| 001-36887 | Warner Chilcott Limited Cannon’s Court 22 Victoria Street Hamilton HM 12 Bermuda (441) 295-2244 |
Bermuda | 98-0496358 | |||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Name of Each Exchange on Which Registered | |
| Allergan plc Ordinary Shares, $0.0001 par value Allergan plc 5.500% Mandatory Convertible Preferred Shares, Series A, par value of $0.0001 Actavis Funding SCS $500,000,000 Floating Rate Notes due 2016* *Notes issued by Actavis Funding SCS and guaranteed by Warner Chilcott Limited |
New York Stock Exchange New York Stock Exchange New York Stock Exchange |
Securities registered pursuant to Section 12(g) of the Act:
None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
| Allergan plc | Yes x | No ¨ | ||
| Warner Chilcott Limited | Yes x | No ¨ |
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
| Allergan plc | Yes ¨ | No x | ||
| Warner Chilcott Limited | Yes ¨ | No x |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:
| Allergan plc | Yes x | No ¨ | ||
| Warner Chilcott Limited | Yes x | No ¨ |
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
| Allergan plc | Yes x | No ¨ | ||
| Warner Chilcott Limited | Yes x | No ¨ |
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
| Allergan plc | ¨ | |
| Warner Chilcott Limited | x |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Allergan plc | Large accelerated filer | x | Accelerated filer | ¨ | ||||
| Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ | |||||
| Warner Chilcott Limited | Large accelerated filer | ¨ | Accelerated filer | ¨ | ||||
| Non-accelerated filer | x (Do not check if a smaller reporting company) | Smaller reporting company | ¨ | |||||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
| Allergan plc | Yes ¨ | No x | ||
| Warner Chilcott Limited | Yes ¨ | No x |
The aggregate market value of the voting and non-voting stock held by non-affiliates of Allergan plc as of June 30, 2015, based upon the last sale price reported for such date on the New York Stock Exchange, was $119.0 billion. The calculation of the aggregate market value of voting and non-voting stock excludes Class A ordinary shares of Allergan plc held by executive officers, directors, and stockholders that the registrant concluded were affiliates of Allergan plc on that date.
Number of shares of Allergan plc’s Ordinary Shares outstanding on February 15, 2016: 394,687,384
This Annual Report on Form 10-K is a combined report being filed separately by two different registrants: Allergan plc and Warner Chilcott Limited. Warner Chilcott Limited is an indirect wholly owned subsidiary of Allergan plc. The information in this Annual Report on Form 10-K is equally applicable to Allergan plc and Warner Chilcott Limited, except where otherwise indicated. Warner Chilcott Limited meets the conditions set forth in General Instruction H(1)(a) and (b) of Form 10-K and, to the extent applicable, is therefore filing this form with a reduced disclosure format.
DOCUMENTS INCORPORATED BY REFERENCE
Certain information required by Part III of this Annual Report on Form 10-K (“Annual Report”) is incorporated by reference from the Allergan plc proxy statement to be filed pursuant to Regulation 14A with respect to the Registrant’s Annual Meeting of Shareholders to be held on or about May 5, 2016.
Explanatory Note
This Amendment No. 1 on Form 10-K/A (the “Amendment”) is a combined report being filed separately by two registrants: Allergan plc and its indirect wholly-owned subsidiary, Warner Chilcott Limited (each, the “Company”).
Each Company is filing this Amendment to its Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2015, filed with the Securities and Exchange Commission on February 26, 2016, solely to file an amended Exhibit 21.1, List of Subsidiaries of each Company. Certain subsidiaries of each Company were inadvertently omitted from the original filing Exhibit 21.1 to the Form 10-K.
As required by the applicable rules, currently-dated Section 302 certifications from each Company’s Chief Executive Officer and Chief Financial Officer are included as exhibits to this Amendment. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted.
Except as described above, no other revisions or amendments have been made to any other portion of the Form 10-K. This Amendment does not reflect events that may have occurred after February 26, 2016, the date of the original filing of the Form 10-K, or modify or update any disclosures that may have been affected by subsequent events.
PART IV
Item 15. Exhibits, Financial Statement Schedules
The following documents are filed as exhibits to this report:
| Exhibit |
Exhibit Description | |
| 21.1 | List of subsidiaries | |
| 31.1 | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2 | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to the Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 4th day of April, 2016.
| ALLERGAN plc | ||
| By: | /s/ A. Robert D. Bailey | |
| A. Robert D. Bailey | ||
| EVP, Chief Legal Officer and Corporate Secretary | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this Amendment No. 1 to the Annual Report has been signed below by the following persons and in the capacities indicated on the 4th day of April, 2016.
| Signature |
Title | |
| * |
Executive Chairman, Director | |
| Paul M. Bisaro | ||
| * |
Chief Executive Officer, President, Director | |
| Brenton L. Saunders | ||
| * |
Chief Financial Officer | |
| Maria Teresa Hilado | ||
| * |
Chief Accounting Officer | |
| James D’Arecca | ||
| * |
Director | |
| Nesli Basgoz, M.D. | ||
| * |
Director | |
| James H. Bloem | ||
| * |
Director | |
| Christopher W. Bodine | ||
| * |
Director | |
| Christopher J. Coughlin | ||
| * |
Director | |
| Michael R. Gallagher | ||
| * |
Director | |
| Catherine M. Klema | ||
| * |
Director | |
| Peter J. McDonnell, M.D. | ||
| * |
Director | |
| Patrick J. O’Sullivan | ||
| * |
Director | |
| Ronald Taylor | ||
| * |
Director | |
| Fred Weiss | ||
| *By: | /s/ A. Robert D. Bailey | |
| A. Robert D. Bailey | ||
| Attorney-in-fact |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Amendment No. 1 to the Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 4th day of April, 2016.
| WARNER CHILCOTT LIMITED | ||
| By: | /s/ A. Robert D. Bailey | |
| A. Robert D. Bailey | ||
| Secretary | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this Amendment No. 1 to the Annual Report has been signed below by the following persons and in the capacities indicated on the 4th day of April, 2016.
| Signature |
Title | |
| /s/ Claire Gilligan |
President (Principal Executive Officer) | |
| Claire Gilligan | ||
| /s/ Robert Whiteford Robert Whiteford |
Vice President, Director of Finance and Assistant Corporate Secretary (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ A. Robert D. Bailey |
Authorized Representative in the United States | |
| A. Robert D. Bailey | ||
| /s/ Claire Gilligan |
Director | |
| Claire Gilligan | ||
| /s/ Robert Whiteford |
Director | |
| Robert Whiteford | ||
| /s/ Tony Hynds |
Director | |
| Tony Hynds | ||
EXHIBIT INDEX
| Exhibit |
Exhibit Description | |
| 21.1 | List of subsidiaries | |
| 31.1 | Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 31.2 | Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
Exhibit 21.1
Subsidiaries of Allergan plc and Warner Chilcott Limited as of December 31, 2015*
| Name |
Jurisdiction of Incorporation | |
| 3948587 Canada Inc. |
Canada | |
| Abri Pharmaceuticals Company |
Canada | |
| Actavis S.à r.l. |
Luxembourg | |
| Actavis S.à r.l. Luxembourg, Zweigniederlassung Steinhausen |
Switzerland | |
| Actavis Asia Pacific Private Limited |
Singapore | |
| Actavis (Cyprus) Limited |
Cyprus | |
| Actavis (MEEA) FZE |
United Arab Emirates | |
| Actavis (Pty) Ltd. (f/k/a Watson Pharma (Pty) Ltd.) |
South Africa | |
| Actavis A/S |
Denmark | |
| Actavis A/S Sucursal Portugese Branch |
Portugal | |
| Actavis AB |
Sweden | |
| Actavis Acquisition 1 S.à r.l. (Irish Branch) |
Ireland | |
| Actavis Acquisition 1 S.à r.l. (f/k/a Watson Pharma S. à r.l.) |
Luxembourg | |
| Actavis Acquisition 2 S.à r.l. (f/k/a Watson Pharma Actavis S.à r.l.) |
Luxembourg | |
| Actavis Australia Pty Ltd. |
Australia | |
| Actavis Capital S.à r.l. (f/k/a Actavis WC Holding S. a r.l.) |
Luxembourg | |
| Actavis Capital S.à r.l., Luxembourg, Zweigniederlassung Zug Branch |
Switzerland | |
| Actavis CZ a.s. |
Czech Republic | |
| Actavis d.o.o. Belgrade |
Serbia | |
| Actavis Dutch Holding BV |
Netherlands, The | |
| Actavis EAD |
Bulgaria | |
| Actavis ehf. |
Iceland | |
| Actavis Elizabeth LLC |
US - Delaware | |
| Actavis Export International Limited |
Malta | |
| Actavis Farmaceutica Ltda (f/k/a Arrow Farmaceutica Ltda) |
Brazil | |
| Actavis Finance S.à r.l. |
Luxembourg | |
| Actavis Finance ehf. |
Iceland | |
| Actavis Finance S.à r.l. Co. |
US - Florida | |
| Actavis Funding SCS |
Luxembourg | |
| Actavis GmbH |
Austria | |
| Actavis Group ehf. |
Iceland | |
| Actavis Group PTC ehf. |
Iceland | |
| Actavis Holding 2 S.à r.l. (f/k/a WatsonPhHldg 2 S.a r.l.) |
Luxembourg | |
| Actavis Holding AB |
Sweden | |
| Actavis Holding Asia BV |
Netherlands, The | |
| Actavis Holding Germany GmbH |
Germany | |
| Actavis Holdings South Africa (Pty) Ltd. (f//k/a Watson Pharma Holdings South Africa (Pty) Ltd.) |
South Africa | |
| Actavis Holdings UK II Limited |
UK | |
| Actavis Holdings UK Ltd. |
UK | |
| Actavis Hong Kong Limited |
Hong Kong | |
| Actavis Hungary Kft |
Hungary | |
| Actavis Ilaclari AS |
Turkey | |
| Actavis International Holding S.à r.l. (f/k/a Watson PhHldg.) |
Luxembourg | |
| Actavis International Limited |
Malta | |
| Actavis Ireland Holding Limited |
Ireland | |
| Actavis Ireland Limited |
Ireland | |
| Actavis Isle of Man Limited |
Isle of Man | |
| Actavis Istanbul Ilac Sanayi Ve Ticaret Limited Sirketi |
Turkey | |
| Actavis Italy S.p.A. |
Italy | |
| Actavis Kadian LLC |
US - Delaware | |
| Actavis K.K. |
Japan | |
| Actavis Laboratories FL, Inc. (f/k/a Watson Laboratories, Inc. Florida) |
US - Florida | |
| Actavis Laboratories NY, Inc. (f/k/a Watson Laboratories, Inc. (Copiague)) |
US - New York |
| Actavis Laboratories UT, Inc. (f/k/a Watson Laboratories, Inc. (Salt Lake City)) |
US - Delaware | |
| Actavis LLC |
US - Delaware | |
| Actavis Limited |
Malta | |
| Actavis Luxembourg International S.à r.l. |
Luxembourg | |
| Actavis Malta Limited |
Malta | |
| Actavis Mid Atlantic LLC |
US - Delaware | |
| Actavis New Zealand Limited (f/k/a Arrow Pharm (NZ) Ltd) |
New Zealand | |
| Actavis Nordic A/S |
Denmark | |
| Actavis Norway AS |
Norway | |
| Actavis Operations EOOD |
Bulgaria | |
| Actavis OY (Finland) |
Finland | |
| Actavis Pharma (Pty) Ltd. (f/k/a Watson Pharma No 1 (Pty) Ltd.) |
South Africa | |
| Actavis Pharma Company (f/k/a Cobalt Ph. & Arrow Ph. OTC) |
Canada | |
| Actavis Pharma Development Centre Private Limited |
India | |
| Actavis Pharma Holding S.à r.l. (f/k/a WatsonPharma Holding |
Luxembourg | |
| Actavis Pharma Holding 4 ehf (APH4) |
Iceland | |
| Actavis Pharma Holding 5 ehf (APH5) |
Iceland | |
| Actavis Pharma Iberia S.L.U. (f/k/a Warner Chilcott Iberia S.L.U.) |
Spain | |
| Actavis Pharma Inc.(f/k/a Watson Pharma, Inc.) |
US - Delaware | |
| Actavis Pharma Private Limited |
India | |
| Actavis Pharma Pty Ltd. (f/k/a Watson Pharma Pty Ltd) |
Australia | |
| Actavis Pharma S. de R.L. de C.V. (f/k/a WatsonPh. S. de RL de CV) |
Mexico | |
| Actavis Pharmaceuticals NJ, Inc. (f/k/a Watson Pharmaceuticals (NJ) Inc.) |
US - Delaware | |
| Actavis Polska Sp. z.o.o. |
Poland | |
| Actavis Pty Ltd (f/k/a/ Ascent Pharmaceuticals Pty Ltd) |
Australia | |
| Actavis Puerto Rico Holdings, Inc. |
US - Delaware | |
| Actavis S. de R.L. de C.V. |
Mexico | |
| Actavis s.r.o. |
Slovak Republic | |
| Actavis Sdn. Bhd (f/k/a Ascent PharmahealthMalaysiaSdn.) |
Malaysia | |
| Actavis Services (Asia) Limited (f/k/a Marrow Holdings Ltd.) |
Malta | |
| Actavis Services (Asia) Limited Beijing Representative Office |
China | |
| Actavis South Atlantic LLC |
US - Delaware | |
| Actavis Specialty Pharmaceuticals Co. (f/k/a Watson Pharma Co) |
Canada | |
| Actavis SRL |
Romania | |
| Actavis Switzerland AG |
Switzerland | |
| Actavis Totowa LLC |
US - Delaware | |
| Actavis UK Limited |
UK | |
| Actavis Ukraine LLC |
Ukraine | |
| Actavis US Holding LLC |
US - Delaware | |
| Actavis W.C. Holding Inc. |
US - Delaware | |
| Actavis WC 1 S.a r.l. (f/k/a WC Luxembourg S. a r.l.) |
Luxembourg | |
| Actavis WC 2 S.a r.l. (f/k/a WC Luxco S.à r.l.) |
Luxembourg | |
| Actavis WC 3 S.a r.l. (f/k/a WC Luxco Holdings S.à r.l. ) |
Luxembourg | |
| Actavis, Inc. |
US - Nevada | |
| Actavis, Inc. II SCS |
Luxembourg | |
| Actavis, Inc. SCS (f/k/a Watson Pharmaceuticals, Inc. SCS) |
Luxembourg | |
| AGN Seabreeze, LLC |
US - Delaware | |
| AHI C.V. |
Netherlands, The | |
| AHI CV HoldCo, LLC |
US - Delaware | |
| Alet Pharmaceuticals Industrial and Commercial Societe Anonyme |
Greece | |
| Allergan (Thailand) Limited |
Thailand | |
| Allergan AG |
Switzerland | |
| Allergan ApS |
Denmark | |
| Allergan AS |
Norway | |
| Allergan Asia Limited |
Hong Kong | |
| Allergan Australia Pty Limited |
Australia | |
| Allergan B.V. |
Netherlands, The | |
| Allergan Baltics, UAB |
Lithuania | |
| Allergan Baltics, UAB Eesti filiaal |
Estonia Branch |
| Allergan Baltics, UAB Latvijas filias |
Latvia | |
| Allergan Biologics Ltd. (f/k/a Actavis Biodesign Ltd., Eden Biodesign Ltd.) |
UK | |
| Allergan Botox |
Ireland | |
| Allergan Bulgaria EOOD |
Bulgaria | |
| Allergan C.I.S. SARL |
Russian Federaion | |
| Allergan Costa Rica S.R.L |
Costa Rica | |
| Allergan CZ s.r.o. |
Czech Republic | |
| Allergan d.o.o. Beograd |
Serbia | |
| Allergan de Colombia S.A. |
Colombia | |
| Allergan de Venezuela, C.A. |
Venzuela | |
| Allergan Development I |
Ireland | |
| Allergan Development II |
Ireland | |
| Allergan Development Ventures I Ireland |
Ireland | |
| Allergan Development Ventures I LP |
Bermuda | |
| Allergan Development Ventures I UK |
UK | |
| Allergan France SAS |
France | |
| Allergan Healthcare India Private Limited |
India | |
| Allergan Healthcare Philippines, Inc. |
Philippines | |
| Allergan Hellas Pharmaceuticals S.A. |
Greece | |
| Allergan Holdings 2 BV |
Netherlands, The | |
| Allergan Holdings B Ltd. |
Bermuda | |
| Allergan Holdings B.V. |
Netherlands Antilles | |
| Allergan Holdings B1, Unlimited |
Bermuda | |
| Allergan Holdings B2 Unlimited |
Bermuda | |
| Allergan Holdings C Ltd |
Cayman Island | |
| Allergan Holdings France SAS |
France | |
| Allergan Holdings Limited |
UK | |
| Allergan Holdings S. à r.l. |
Luxembourg | |
| Allergan Holdings Unlimited Company (f/k/a Furiex Holdings Unlimied Company) |
Ireland | |
| Allergan Holdings, Inc. |
US - Delaware | |
| Allergan Hong Kong Limited |
Hong Kong | |
| Allergan Ilaclari Ticaret A.S. |
Turkey | |
| Allergan Inc. |
Canada | |
| Allergan India Private Limited |
India | |
| Allergan Industrie SAS |
France | |
| Allergan Information Consulting (Shanghai) Co., Ltd. |
China | |
| Allergan International YK |
Japan | |
| Allergan Ireland Holdings Ltd. |
Ireland | |
| Allergan Israel Limited |
Israel | |
| Allergan Japan KK |
Japan | |
| Allergan KK |
Japan | |
| Allergan Korea Ltd |
Korea | |
| Allergan Laboratorios Limitada |
Chile | |
| Allergan Limited |
UK | |
| Allergan Luxembourg S.à r.l. |
Luxembourg | |
| Allergan Malaysia Sdn. Bhd. |
Malaysia | |
| Allergan Medical GmbH (f/k/a Allergan Medical S.à r.l.) |
Switzerland | |
| Allergan Medical Pty Ltd. |
Australia | |
| Allergan Middle East FZ-LLC |
United Arab Emirates | |
| Allergan N.V. |
Belgium | |
| Allergan New Zealand Ltd. |
New Zealand | |
| Allergan NK |
Japan | |
| Allergan Norden AB |
Sweden | |
| Allergan Norden AB (Finnish branch) |
Finland | |
| Allergan Optical Irvine, Inc. |
US - California | |
| Allergan Pharmaceuticals (Proprietary) Ltd. |
South Africa | |
| Allergan Pharmaceuticals Holdings (Ireland) |
Ireland | |
| Allergan Pharmaceuticals International Limited (f/k/a Aptalis Pharma Ltd.). |
Ireland | |
| Allergan Pharmaceuticals Ireland |
Cayman Island |
| Allergan Pharmaceuticals Ireland | Ireland | |
| Allergan Pharmaceuticals Taiwan Co. Ltd. | Taiwan | |
| Allergan Productos Farmaceuticos S.A. | Argentina | |
| Allergan Produtos Farmaceuticos Ltda. | Brazil | |
| Allergan Property Holdings, LLC | US - Delaware | |
| Allergan Puerto Rico Holdings, Inc. | US - Delaware | |
| Allergan S.A. | Spain | |
| Allergan S.p.A. | Italy | |
| Allergan Sales Puerto Rico, Inc. | US - California | |
| Allergan Sales, LLC. | US - Delaware | |
| Allergan Services BV | Netherlands, The | |
| Allergan Services International, Limited | Ireland | |
| Allergan Servicios Profesionales, S. de R.L. de C.V. | Mexico | |
| Allergan Singapore Pte. Ltd. | Singapore | |
| Allergan Singapore Pte. Ltd. Indonesia Rep Office | Indonesia | |
| Allergan Singapore Pte. Ltd. Vietnam Rep Office | Vietnam | |
| Allergan SK S.r.o. | Slovak Republic | |
| Allergan Sp. Z.o.o. | Poland | |
| Allergan Specialty Therapeutics, Inc. | US - Delaware | |
| Allergan SRL | Romania | |
| Allergan UK Group Limited | UK | |
| Allergan UK LLP | UK | |
| Allergan Ukraine, LLC | Ukraine | |
| Allergan USA, Inc. | US - Delaware | |
| Allergan, Inc. | US - Delaware | |
| Allergan, S.A. de C.V. | Mexico | |
| Anda Inc. | US - Florida | |
| Anda Marketing, Inc. | US - Florida | |
| Anda Pharmaceuticals, Inc. | US - Florida | |
| Anda Puerto Rico, Inc | Puerto Rico | |
| Anda Veterinary Supply Inc. | US - Florida | |
| Andrx Corporation | US - Delaware | |
| Andrx Laboratories (NJ), Inc. | US - Delaware | |
| Andrx Labs LLC | US - Delaware | |
| Andrx Pharmaceuticals (Mass), Inc. | US - Florida | |
| Andrx Pharmaceuticals (NC) Equipment, LLC | US - Delaware | |
| Andrx Pharmaceuticals (NC), Inc. | US - Florida | |
| Andrx Pharmaceuticals Equipment #1, LLC | US - Florida | |
| Andrx Pharmaceuticals Sales and Marketing, Inc. | US - Florida | |
| Andrx Pharmaceuticals, LLC | US - Delaware | |
| Andrx South Carolina I, Inc. | US - South Carolina | |
| Anterios, Inc. | US - Delaware | |
| APBI Holdings, LLC | US - North Carolina | |
| Aptalis Holding B.V. | Netherlands, The | |
| Aptalis Holdings, Inc. | US - Delaware | |
| Aptalis Netherlands B.V. | Netherlands, The | |
| Aptalis Pharma Canada ULC | Canada | |
| Aptalis Pharma Export, Inc. | Canada | |
| Aptalis Pharma GmbH | Germany | |
| Aptalis Pharma Ltd. (f/k/a Allergan Pharmaceuticals International Ltd.) |
Ireland | |
| Aptalis Pharma S.r.l. | Italy | |
| Aptalis Pharma SAS | France | |
| Aptalis Pharma UK Limited | UK | |
| Aptalis Pharma US, Inc. | US - Delaware | |
| AqueSys, Inc. | US - Delaware | |
| Arrow ApS | Denmark | |
| Arrow Generics Ltd. | UK | |
| Arrow Group ApS | Denmark | |
| Arrow International Ltd. | Malta |
| Arrow Laboratories Ltd. | Malta | |
| Arrow Lakemedel Aktiebolag | Sweden | |
| Arrow No 7 Ltd. | UK | |
| Arrow Pharma (Malta) Ltd. | Malta | |
| Arrow Pharma HK Limited | Hong Kong | |
| Arrow Pharma Tender (Pty) Ltd. | South Africa | |
| Arrow Supplies Ltd. | Malta | |
| Arrowblue Productos Farmaceuticos SA | Portugal | |
| Ascent Australia Pty Ltd | Australia | |
| Ascent Pharma Pty Ltd. | Australia | |
| Ascent Pharmahealth Asia Pte Ltd | Singapore | |
| Ascent Pharmahealth Hong Kong Limited | Hong Kong | |
| Ascent Pharmahealth Pty Ltd | Australia | |
| Auden McKenzie (Pharma Division) Limited | UK | |
| Auden McKenzie Holdings Limited | UK | |
| Axcan EU LLC | US - Delaware | |
| Axcan France (Invest) S.A.S. | France | |
| Axcan Pharma (Australia) Pty Ltd | Australia | |
| Balkanpharma Dupnitsa AD | Bulgaria | |
| Balkanpharma Healthcare International (Cyprus) Ltd. | Cyprus | |
| Balkanpharma Securitiy EOOD | Bulgaria | |
| Balkanpharma Troyan AD | Bulgaria | |
| Biovena Pharma Sp. z.o.o. | Poland | |
| Biozymes Inc. | Canada | |
| Bowmed Ltd. | UK | |
| Breath Limited | UK | |
| Cerexa Inc. | US - Delaware | |
| Chilcott UK Limited | UK | |
| Circa Pharmaceuticals West, Inc. | US - California | |
| Circa Sub | US - New York | |
| Cobalt Laboratories LLC | US - Delaware | |
| Collagen Aestethics Benelux S.A. | Belgium | |
| Commack Properties, Inc. | US - Delaware | |
| Coventry Acquisition, LLC | US - Delaware | |
| Cybear, LLC | US - Delaware | |
| Del Mar Indemnity Co. Inc. | US - Hawaii | |
| Development Partners, LLC | US - Delaware | |
| Dogwood Pharmaceuticals, Inc. | US - Delaware | |
| Drug House of Australia Pte Ltd | Singapore | |
| Durata Therapeuctics U.S. Limited | US - Delaware | |
| Durata Therapeutics Holding C.V. | Netherlands, The | |
| Durata Therapeutics, Inc. | US - Delaware | |
| Durata Therapeutics International B.V. | Netherlands, The | |
| Durata Therapeutics Limited | UK | |
| Eden Biodesign Inc. | US - Delaware | |
| Eden Biopharm Group Ltd. | UK | |
| Eden Biopharm Ltd. | UK | |
| Eremad Pty Ltd. | Australia | |
| Eurand France S.A.S. | France | |
| Exemplar Pharma LLC | US - Delaware | |
| Femalon SPRL | Belgium | |
| FL Cincinnati I Inc. | US - Delaware | |
| FL Holding C.V. | Netherlands, The | |
| FLI International LLC | US - Delaware | |
| Forest Finance B.V. | Netherlands, The | |
| Forest Healthcare (Branch of Forest Tosara Ltd.) | Netherlands, The | |
| Forest Holdings France S. A.S. | France | |
| Forest Laboratories Canada Inc. | Canada | |
| Forest Laboratories Denmark APS | Denmark |
| Forest Laboratories Deutschland GmbH | Germany | |
| Forest Laboratories France S.A.S. | France | |
| Forest Laboratories Holdings Limited | Ireland | |
| Forest Laboratories Ireland Ltd | Ireland | |
| Forest Laboratories Italy S.R.L. | Italy | |
| Forest Laboratories Osterreich GmbH | Austria | |
| Forest Laboratories Products Corp. | US - Delaware | |
| Forest Laboratories Spain, SL | Spain | |
| Forest Laboratories UK Ltd. | UK | |
| Forest Laboratories, LLC | US - Delaware | |
| Forest Pharma B.V. | Netherlands, The | |
| Forest Pharmaceuticals, Inc. | US - Delaware | |
| Forest Research Institute, Inc. | US - New Jersey | |
| Forest Tosara Ltd. | Ireland | |
| FRX Churchill Holdings, Inc. | US - Delaware | |
| Furiex Pharmaceuticals, LLC | US - Delaware | |
| Gastro Services Pty Ltd | Australia | |
| GenuPro, LLC | US - North Carolina | |
| Herbert Laboratories | US - California | |
| Inamed Corporation | US - Delaware | |
| Inamed Development Corporation | US - California | |
| Inamed Do Brazil Ltda | Brazil | |
| Inamed, LLC | US - Delaware | |
| Inwood Laboratories, Inc. | US - New York | |
| Ireland Actavis Finance Ltd. | Ireland | |
| Kythera Biopharmaceuticals (Europe) Limited | UK | |
| Kythera Biopharmaceuticals Australia Pty Ltd. | Australia | |
| Kythera Biopharmaceuticals, Inc. | US - Delaware | |
| Kythera Holdings Ltd. | Bermuda | |
| Lime Pharma Limited | UK | |
| LLC Actavis | Russia | |
| Lotus Laboratories Private Ltd. | India | |
| M8 Holdings LLC | US - Delaware | |
| Makewhey Products Pty LTd. | South Africa | |
| Makoff R&D Laboratories, Inc. | US - California | |
| MAP Pharmaceuticals, Inc. | US - Delaware | |
| Marrow Pharmaceuticals Research & Development Co Ltd. | China | |
| Marsam Pharma, LLC | US - Delaware | |
| McGahn Ireland Holdings Ltd. | Ireland | |
| McGahn Limited | Ireland | |
| McGahn Medical BV | Netherlands, The | |
| Med All Enterprise Consulting (Shanghai) Co. Ltd. | China / Shanghai | |
| Medis ehf. | Iceland | |
| Medis Pharma BV (f/k/a Actavis Holding BV) | Netherlands, The | |
| Medis Pharma France S.A.S. | France | |
| Medis Pharma GmbH | Germany | |
| Medis Pharma Pty Ltd. (f/k/a Spirit Pharmaceuticals Pty Ltd) | Australia | |
| Medis-Danmark A/S | Denmark | |
| Milbrook (NI) Limited | UK | |
| MPEX London Limited | UK | |
| MPEX Pharmaceuticals, Inc. | US - Delaware | |
| MSI, Inc | US - Delaware | |
| Natrapac Inc. | US - Utah | |
| Naurex Inc. | US - Delaware | |
| Nicobrand Limited | UK | |
| Northwood Medical Innovation, Ltd. | UK | |
| NRIM Limited | UK | |
| Oculeve, Inc. | US - Delaware | |
| Odyssea Pharma SPRL | Belgium |
| Oncopharma AG |
Switzerland | |
| Pacific Pharma, Inc. |
US - Delaware | |
| Paomar Plc. |
Cyprus | |
| Pharm-Allergan GmbH |
Germany | |
| Pharm-Allergan GmbH Austria branch |
Austria | |
| PharmaPack International BV |
Netherlands, The | |
| Pharmascript Pharmaceuticals Limited |
South Africa | |
| Pharmax Holding Limited |
UK | |
| Pharmax Limited |
UK | |
| PT Actavis Indonesia |
Indonesia | |
| R&D Ferriecit Capital Resources, Inc. |
US - California | |
| R&D New Media Services Inc. |
US - California | |
| R&D Pharmaceutical, Inc. |
US - California | |
| R&D Research & Development Corp. |
US - California | |
| Referral-Net (Pty) Ltd. |
South Africa | |
| Robin Hood Holdings Ltd. |
Malta | |
| Royce Laboratories, Inc. |
US - Florida | |
| Royce Research & Development Limited Partnership I |
US - Florida | |
| Royce Research Group, Inc. |
US - Florida | |
| Rugby Laboratories, Inc. |
US - New York | |
| RxAPS, Inc. |
US - Florida | |
| Schein Bayer Pharmaceutical Services, Inc. |
US - Delaware | |
| Schein Pharmaceutical International, Inc. |
US - Delaware | |
| Schein Pharmaceutical (Bermuda) Ltd |
Bermuda | |
| Scriptpharm Marketing (Pty) Ltd. |
South Africa | |
| Seabreeze LP Holdings, LLC |
US - Delaware | |
| Seabreeze Silicone |
Ireland | |
| Seeker Investments Limited |
British Virgin Islands | |
| Selamine Ltd. |
Ireland | |
| Silicone Engineering Inc. |
US - California | |
| Silom Medical Co., Ltd. |
Thailand | |
| Silom Medical International Co., Ltd. |
Thailand | |
| Sindan Pharma SRL |
Romania | |
| Soosysoo Ltd. |
British Virgin Islands | |
| SourceCF Inhalation Systems, LLC |
US - Delaware | |
| Spear Pharmaceuticals (Pty) Ltd. |
South Africa | |
| Specifar SA |
Greece | |
| Spirit Pharmaceuticals NZ Pty Ltd. |
New Zealand | |
| SR Six, Inc. |
US - Florida | |
| Systemic Pulmonary Delivery, Ltd. |
Bermuda | |
| Tango US Holdings Inc. |
US - Delaware | |
| The Rugby Group, Inc. |
US - New York | |
| The Seabreeze LP Holdings LLC AGN Seabreeze LLC Limited Partner |
Ireland | |
| Tosara Exports Limited |
Ireland | |
| UAB Actavis Baltic |
Lithuania | |
| UAB Actavis Baltic Estonia Branch |
Estonia | |
| UAB Actavis Baltic Latvia Branch |
Latvia | |
| Uteron Pharma SPRL |
Belgium | |
| Valmed Pharmaceuticals, Inc. |
US - New York | |
| Varioraw Percutive Sàrl |
Switzerland | |
| Vicuron Pharmaceuticals, Inc |
US - Delaware | |
| Warner Chilcott (Ireland) Limited |
Ireland | |
| Warner Chilcott (US), LLC |
US - Delaware | |
| Warner Chilcott Acquisition Limited |
UK | |
| Warner Chilcott Australia Pty. Ltd. |
Australia | |
| Warner Chilcott Company, LLC |
Puerto Rico | |
| Warner Chilcott Corporation |
US - Delaware | |
| Warner Chilcott Deutschland GmbH |
Germany | |
| Warner Chilcott Finance LLC |
US - Delaware |
| Warner Chilcott France S.A.S. | France | |
| Warner Chilcott Holdings Company II, Limited | Bermuda | |
| Warner Chilcott Holdings Company III, Limited | Bermuda | |
| Warner Chilcott Intermediate (Ireland) Limited | Ireland | |
| Warner Chilcott Italy S.r.l. | Italy | |
| Warner Chilcott Leasing Equipment Inc. | US - Delaware | |
| Warner Chilcott Limited | Bermuda | |
| Warner Chilcott Nederland B.V. | Netherlands, The | |
| Warner Chilcott Pharmaceuticals B.V.B.A. | Belgium | |
| Warner Chilcott Pharmaceuticals S. àr.l. | Switzerland | |
| Warner Chilcott Pharmaceuticals UK Limited | UK | |
| Warner Chilcott plc** | Ireland | |
| Warner Chilcott Research Laboratories Limited | UK | |
| Warner Chilcott Sales (US), LLC | US - Delaware | |
| Warner Chilcott UK Limited | UK | |
| Watson Cobalt Holdings, LLC | US - Delaware | |
| Watson Diagnostics Inc. | US - Delaware | |
| Watson Laboratories Inc. (Connecticut) | US - Connecticut | |
| Watson Laboratories Inc. (Corona) | US - Nevada | |
| Watson Laboratories Inc. Ohio | US - New York | |
| Watson Laboratories LLC | US - Delaware | |
| Watson Laboratories S. de R.L. de C.V. | Mexico | |
| Watson Laboratories, Inc. (Arizona) | US - Delaware | |
| Watson Management Corporation | US - Florida | |
| Watson Manufacturing Services, Inc. | US - Delaware | |
| Watson Merger Sub Inc. | US - Delaware | |
| Watson Pharma Private Limited | India | |
| Watson Pharmaceuticals (Asia) Ltd. | British Virgin Islands | |
| Watson Pharmaceuticals (China) Limited | British Virgin Islands | |
| Watson Pharmaceuticals International Ltd. | British Virgin Islands | |
| Watson Therapeutics, Inc. | US - Florida | |
| WC Pharmaceuticals I Limited | Gibraltar | |
| WC Pharmaceuticals II Limited | Gibraltar | |
| Willow Pharmaceuticals (Australia) Pty Ltd. | Australia | |
| WP Holdings Ltd. | British Virgin Islands | |
| Zdravlje AD | Serbia | |
| Zelphy 1308 (Pty) Ltd. | South Africa |
| * | Except as indicated, all subsidiaries listed are of Allergan plc and Warner Chilcott Limited. |
| ** | Direct parent of Warner Chilcott Limited. |
Exhibit 31.1
Certification of Chief Executive Officer
Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
I, Brenton L. Saunders, President and Chief Executive Officer, certify that:
1. I have reviewed this annual report on Form 10-K/A of Allergan plc and Warner Chilcott Limited; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
Date: April 4, 2016
| By: | /s/ BRENTON L. SAUNDERS | |
| Brenton L. Saunders | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) |
Exhibit 31.2
Certification of Chief Financial Officer
Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934
I, Maria Teresa Hilado, Chief Financial Officer, certify that:
1. I have reviewed this annual report on Form 10-K/A of Allergan plc and Warner Chilcott Limited; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
Date: April 4, 2016
| By: | /s/ MARIA TERESA HILADO | |
| Maria Teresa Hilado | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||